Vice President, Investor Relations and Corporate Communications
Christopher Keenan joined Pliant Therapeutics as Vice President, Investor Relations and Corporate Communications in November 2020 with responsibility for implementing strategic investor relations initiatives for Pliant and our shareholders. Mr. Keenan brings over 20 years of investor relations/ corporate communications experience having served in the role in small to large market capitalized public companies within the pharmaceutical, biotechnology, medical device, and specialty pharmaceutical industries.
Prior to Pliant, Mr. Keenan held the role of Vice President, Investor Relations and Corporate Communications at CytomX Therapeutics. Prior to this, he held the lead investor relations role at Depomed, Peregrine Pharmaceuticals, Cytokinetics and Aradigm. He began his investor relations career at Isis Pharmaceuticals (now Ionis Pharmaceuticals) and his professional career at The Weinberg Group, a scientific and regulatory consultancy to the biopharmaceutical industry.
Mr. Keenan received his B.A. in English from Kenyon College.
Pliant is led by a team of world-renowned fibrosis researchers and highly experienced drug developers focused on translating science into novel therapies for patients in need.